ECE2017 Eposter Presentations: Thyroid Thyroid (non-cancer) (260 abstracts)
1Trakya University, Medical Faculty, Department of Endocrinology and Metabolism, Edirne, Turkey; 2Trakya University, Medical Faculty, Department of Pathology, Edirne, Turkey; 3Trakya University, Medical Faculty, Department of Surgery, Edirne, Turkey; 4Trakya University, Medical Faculty, Department of Nuclear Medicine, Edirne, Turkey.
Aim: The incidence of nodular thyroid disease is high among patients with insulin resistance. The aim of this study is to evaluate the relationship between BRAFV600E mutation and insulin resistance in the patients with papillary thyroid cancer.
Materials and methods: We examined clinical and laboratory data of 103 patients who had been followed up by our department between the years 2010 and 2015. The diagnosis of insulin resistance (IR) was made when the homeostasis model assesment of insulin resistance (HOMA-IR) index was higher than 2.5.
Results: 90 (87.4%) of 103 patients were female, while 13 (12.6%) of them were male. HOMA-IR was ≥ 2.5 in 58 (56.3%) patients and <2.5 in 45 (43.7%) patients. 19 of the patients were BRAFV600E mutation (+), while BRAFV600E mutation was (−) in 84 cases. Among 58 patients with insulin resistance, 46 (79.3%) patients were BRAFV600E mutation (−) and 12 (19.7%) patientswere BRAFV600E mutation (−). There was no statistically significant relationship between BRAFV600E mutation and HOMA-IR in terms of demographic data, clinical and histopathologic results.
Conclusion: In this study, no statistically significant relationship was detected between insulin resistance and BRAFV600E mutation among the patients with PTC.